Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Marqeta Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Marqeta Inc trades at $18.39 (market cap $1.89B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 4.7× Marqeta Inc's market cap, and Marqeta Inc is more actively traded (809,068 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Marqeta Inc for 44 Days on average.
| KYMR | MQ | |
|---|---|---|
Market Cap | $8.88B | $1.89B |
Volume | 1,028,790 | 809,068 |
Sector | Health | Technology |
52-Week High | $127.31 | $20.32 |
52-Week Low | $55.80 | $15.04 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $8.27B | $1.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marqeta (MQ) trades at $18.56, up 1.48% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported three consecutive quarterly EPS beats, with Q3 2026 results expected soon. Revenue has recovered from $507M in 2024 to $625M in 2025, though net income remains negative. Positive cash flow trends emerged in 2025, with net cash flow turning positive at $86M.
The outlook is mixed: strong operational momentum and partnerships (e.g., with Google and BVNK) support growth, but high valuation ratios (P/E 206.22) and thin net margins (1.53%) pose risks. Analyst consensus is cautious with a $11.38 price target, implying downside, yet institutional sentiment is divided amid earnings improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
